The Prevalence of HIV Drug Resistance among Treatment-failure Individuals and Treatment-nave Individuals in China:A Meta-analysis

作     者：WU Jing NORRIS Jessie LIU Hui Xin LI Zheng SU Ying Ying ZHU Lin WANG Ning 

作者机构：National Center for AIDS/STD Control and PreventionChina Center for Disease and Prevention School of Agroforestry & Medicinethe Open University of China 

出 版 物：《Biomedical and Environmental Sciences》 (生物医学与环境科学（英文版）)

年 卷 期：2014年第27卷第11期

页      面：858-871页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by the National Megaprojects of Science Research for the 12th Five-Year Plan(2012ZX10001-001) 

主　　题：HIV Drug resistance Meta analysis China 

摘      要：Objective To understand drug resistance prevalence among treatment-failure and treatment-nave HIV-positive individuals in *** We searched five electronic databases（Wanfang,CNKI,CQVIP,SinoMed,and Pubmed） for studies of HIV drug ***-effects models were carried out to estimate the prevalence of drug resistance among treatment-failure and treatment-nave individuals,*** The estimated nationwide rates of HIV drug resistance to any-class drugs among treatment-failure and treatment-nave individuals were 57%（95% CI：49%-65%） and 3.23%（95% CI：2.47%-4.07%）,*** the drug classes,the prevalence of resistance to PIs was low（1.45%;95% CI：0.73%-2.33%） in treatment-failure individuals,although high rates of resistance to NNRTIs（54%;95% CI：45%-63%） and NRTIs（40%;95% CI：32%-49%） were *** to any-class drugs,NNRTIs and NRTIs manifested regional differences,but resistance to PIs did *** correlations were observed between resistance to NNRTIs and NRTIs among treatment-failure and treatment-nave individuals,*** The prevalence of HIV drug resistance to NNRTIs and NRTIs among treatment-failure individuals was *** contrast,the prevalence of drug resistance among treatment-nave individuals was *** epidemics of drug resistance matched current treatment strategies and interventions in *** for HIV drug resistance is necessary to assess the sustainability and durability of current treatment regimens.